| Literature DB >> 24278081 |
Maciej Sopata1, Elżbieta Tomaszewska, Zygmunt Muszyński, Maria Ciupińska, Aleksandra Kotlińska-Lemieszek.
Abstract
INTRODUCTION: Neoplastic ulcers are chronic and, most often, irreversible lesions caused by proliferation of tumor cells infiltrating and damaging skin tissues. The treatment of neoplastic ulcers is a very difficult and time-consuming process. So, is very important to find methods of controlling this type of chronic wounds. AIM: To evaluate the efficiency of monitored treatment of neoplastic ulcers by means of providing moist wound environment dressings and antiseptic to the group of patients with an advanced stage of tumor, with particular focus on the impact of the treatment applied on the clinical condition of the ulcers; to evaluate the impact of the treatment applied on the dynamics of bacterial flora in neoplastic ulcers, with particular focus on the presence of alarm pathogens; to conduct a risk analysis of the occurrence of local and systemic complications during treatment.Entities:
Keywords: antiseptics; cancer ulceration; microbiology; octenidine; topical treatment
Year: 2013 PMID: 24278081 PMCID: PMC3834706 DOI: 10.5114/pdia.2013.37034
Source DB: PubMed Journal: Postepy Dermatol Alergol ISSN: 1642-395X Impact factor: 1.837
Characteristics of patients with neoplastic ulcers (n = 30)
| Men/women | 13/17 |
|---|---|
| Age, range, | 24–92, 63.2 ±12.2, 64 |
| Primary diagnosis: | |
| Breast cancer | 9 (30%) |
| Vulva cancer | 6 (20%) |
| Skin cancer | 5 (16.7%) |
| Head and neck cancer | 4 (13.3%) |
| Bone cancer | 3 (10%) |
| Other | 3 (10%) |
| Location of the ulcer: | |
| Breast | 9 (30%) |
| Skin | 8 (26.7%) |
| Groin area | 5 (16.7%) |
| Vulva | 4 (13.3%) |
| Head and neck | 4 (13.3%) |
| Duration of ulceration, | 0.2–3.8, 1.8 ±0.7, 1.6 |
| Body mass, range, | 44–136, 54.2 ±12.26, 55 |
| BMI, range, | 12.4–36.2, 24.2 ±4.8, 24 |
| Mean performance status: | |
| ECOG | 3.5 |
| Karnofsky | 55 |
| Laboratory diagnostics: | |
| Hgb, | 7.12 ±1.18 |
| Protein, | 6.28 ±0.64 |
| Albumins, | 2.82 ±0.32 |
Clinical changes in neoplastic ulcers at the baseline and after 3 weeks of treatment
| Clinical assessment of the wound | Clinical status | Baseline of the study Number of wounds ( | End of the study Number of the wounds ( | Statistic significance |
|---|---|---|---|---|
| Necrotic tissue amount | Significant | 13 | 0 |
|
| Moderate | 6 | 8 | ||
| Low | 2 | 6 | ||
| Lack | 9 | 11 | ||
| Exudate level | Significant | 15 | 0 |
|
| Moderate | 8 | 8 | ||
| Low | 7 | 15 | ||
| Lack | 0 | 2 | ||
| Pain level | Significant | 7 | 0 |
|
| Moderate | 10 | 8 | ||
| Low | 6 | 8 | ||
| Lack | 7 | 9 | ||
| Malodour level | Significant | 3 | 0 |
|
| Moderate | 4 | 3 | ||
| Low | 7 | 3 | ||
| Lack | 16 | 19 |
Strains isolation at the beginning of study
| Number of isolated strains | Number of patients | Percentage |
|---|---|---|
| 2 | 6 | 20 |
| 3 | 12 | 40 |
| 4 | 12 | 40 |
| Together | 30 | 100 |
Species and frequency of occurrence of bacteria isolated at the baseline of study (n = 53)
| Bacterial species | Number of strains | Percentage of strains |
|---|---|---|
| Gram(+) | 27 | 50.9 |
|
| 14 | 26.4 |
|
| 5 | 9.4 |
|
| 1 | 1.9 |
|
| 7 | 13.2 |
| Gram(–) | 26 | 49.1 |
|
| 9 | 17.0 |
|
| 7 | 13.2 |
|
| 2 | 3.8 |
|
| 1 | 1.9 |
|
| 5 | 9.4 |
|
| 1 | 1.9 |
|
| 1 | 1.9 |
| Total | 53 | 100 |
Isolation of strains from neoplastic ulcers at the end of the treatment
| Number of strains | Number of patients | Percentage of patients |
|---|---|---|
| No strains | 20 | 80 |
| 1 | 5 | 20 |
| Total | 25 | 100 |
Persistent bacterial flora isolated from neoplastic ulcers
| Patient number | Beginning of treatment | After 3 weeks |
|---|---|---|
| 4 |
|
|
| 14 |
|
|
| 17 |
|
|
| 21 |
|
|
| 23 |
|
|
Alarm pathogens isolated from the neoplastic ulcers at baseline assessment (n = 53)
| Number of strains ( | Percentage % | Resistance mechanism |
|---|---|---|
|
| 3.8 | MRSA |
|
| 3.8 | HLAR |
|
| 11.3 | ESβL |
|
| 1.9 | ESβL, MβL |
| 11 | 20.8 | Total |
Alarm pathogens isolated from neoplastic ulcers after treatment with octenidine dihydrochloride (n = 5)
| Number of strains | Species | Resistance mechanism |
|---|---|---|
| 2 |
| HLAR |
| 2 |
| ESβL |
| 1 |
| MβL, ESβL |